FZFan Zhou

Fan Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fan Zhou has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Jiawen Zheng

    Department of Gastroenterology,Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing 210046, China; Department of Geriatrics,Zhenjiang Hospital of Chinese Traditional and Western Medicine, Zhenjiang 212000, China

    2 shared publications
  • Bo Peng

    Department of Traditional Chinese Medicine,Affiliated Hospital of Jiangsu University, Zhenjiang 212000, China

    1 shared publication
  • Chenchen Wu

    Department of Gastroenterology, Nanjing Drum Tower Hospital Clinical College of Jiangsu University, Nanjing 210046, China

    1 shared publication
  • Chenchen Wu

    Department of Gastroenterology, Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital Clinical College of Jiangsu University, Nanjing, People’s Republic of China

    1 shared publication
  • Chunyan Peng

    Department of Gastroenterology, Nanjing Drum Tower Hospital Affiliated with Medical School of Nanjing University, Nanjing, People’s Republic of China

    1 shared publication
  • Di Chen

    State Key Laboratory of Cancer Biology & Institute of Digestive Diseases, Xijing Hospital, The Air-Force Military Medical University, Xi'an, Shaanxi, China

    1 shared publication

Latest Publications

  • Open Access

    Development of Predictive Models for Long-Term Endoscopic Response to Ustekinumab in Crohn’s Disease Based on Plasma Proteomics

    by Chenchen Wu, Jiawen Zheng, Xin Qian, Chunyan Peng, Fan Zhou, Lei Wang

    Purpose: Ustekinumab (UST) is effective for Crohn’s disease (CD), yet reliable biomarkers for predicting long-term response remain scarce. This study aimed to identify novel plasma proteomic biomarkers and develop predictive models for long-term endoscopic response to UST therapy in patients. Methods: Baseline plasma inflammatory proteins were profiled using the Olink platform in 40 CD patients treated with UST (20 responders, 20 non-responders). Differentially expressed proteins (DEPs) were identified after adjusting for age, age at diagnosis, and SES-CD scores. Stable DEPs were selected via bootstrap resampling and further validated in an independent patient group from the same center (n=20) using ELISA. Predictive models were constructed using logistic regression, random forest, and support vector machine (SVM) algorithms. Results: Non-responders had elevated baseline interleukin-8 (IL8) and CD6 levels and reduced thymic stromal lymphopoietin (TSLP) compared to responders. ELISA confirmed differential expression of IL8, CD6, and TSLP, with CD6 showing the best diagnostic accuracy (AUC=0.800). The logistic regression model combining these markers achieved an AUC of 0.828 (95% CI: 0.701– 0.954), outperforming random forest (AUC=0.745) and SVM (AUC=0.775). Conclusion: Baseline plasma IL8, CD6, and TSLP are potential predictive biomarkers of long-term endoscopic response to UST in CD, providing a basis for personalized treatment strategies. Plain Language Summary: We analyzed baseline plasma from Crohn’s disease patients receiving ustekinumab and found that elevated levels of IL-8 and CD6, with reduced TSLP expression, predict poor response. Measuring these proteins may guide more personalized treatment decisions.


  • Open Access

    Down-regulation of LRIG1 by miR-20a modulates gastric cancer multidrug resistance

    by Lin Zhou, Xiaowei Li, Fan Zhou, Zhi’an Jin, Di Chen, Pin Wang, Shu Zhang, Yuzheng Zhuge, Yulong Shang, Xiaoping Zou

    Multidrug resistance (MDR) significantly restricts the clinical efficacy of gastric cancer (GC) chemotherapy, and it is critical to search novel targets to predict and overcome MDR. Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) has been proved to be correlated with drug resistance in several cancers. The present study revealed that LRIG1 was overexpressed in chemo-sensitive GC tissues and decreased expression of LRIG1 predicted poor survival in GC patients. We observed that up-regulation of LRIG1 enhanced chemo-sensitivity in GC cells. Interestingly, miR-20a, which was overexpressed in GC MDR cell lines and tissues, was identified to regulate LRIG1 expression by directly targeting its 3′untranslated region. We also found that inhibition of miR-20a suppressed GC MDR, and up-regulation showed opposite effects. Moreover, we demonstrated that the miR-20a/LRIG1 axis regulated GC cell MDR through EGFR mediated PI3K/AKT and MAPK/ERK signaling pathways. Finally, LRIG1 expression in human GC tissues is inversely correlated with miR-20a and EGFR. Taken together, the newly identified miR-20a/LRIG1/EGFR link provides insight into the MDR process of GC, and targeting this axis represents a novel potential therapeutic strategy to block GC chemo-resistance.